INMB
INmune Bio·NASDAQ
--
--(--)
--
--(--)
3.71 / 10
Netural
Analyst coverage is thin—only one Strong Buy with a 0% historical win rate and –17.6% average return. Fund‑flow metrics are positive (score 7.4/10) with overall inflow, though small and large blocks show slight outflows. Market sentiment remains neutral to pessimistic.
Fund Flow Rating
Analyst RatingStrong Buy
Wall Street Opinions
Strong Buy
Strong Buy
100%
Buy
0%
Hold
0%
Sell
0%
Strong Sell
0%
Date2026-03-11
InstitutionLUCID CAPITAL MARKETS
Times predicted1
Historical Win Rate0.0%
What is the analyst consensus for INMB?
- INMB holds a Bearish analyst rating, with 100% of experts assigning a Strong Buy grade. Factoring in net Inflows from order flow data, the comprehensive Sentiment Score stands at 3.71/10 (Netural).
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
